TITLE 7HEALTHCHAPTER 27EMERGENCY MEDICAL SERVICESPART 11SUPPLEMENTAL LICENSING PROVISIONS

7.27.11.2 SCOPE: These rules apply to New Mexico emergency medical services (<u>EMS</u>), including <u>mobile</u> <u>integrated health, community EMS, critical care EMS, special event, healthcare facilities, and other entities that</u> <u>employee and utilize New Mexico licensed EMS personnel.</u> These rules also apply to the service directors and medical directors of those services; approved New Mexico emergency medical service (EMS) training programs and graduates of approved New Mexico EMS training programs; New Mexico licensed EMS personnel including those previously licensed; persons trained, certified or licensed in another state or territory, or certified by the national registry of emergency medical technicians, seeking to acquire licensure in New Mexico; EMS licensing commission; and any other entity associated with the licensing of emergency medical services personnel in New Mexico. In the event of a public health emergency that stresses the emergency medical service system and disrupts delivery of medical services, the New Mexico department of health, working with the emergency medical systems bureau, may limit or expand these rules, and may institute certain crisis standards of care, through emergency rulemaking.

[7.27.11.2 NMAC - Rp, 7.27.11.2 NMAC, 12/12/2017; A, xx/xx/2021]

7.27.11.8 SCOPES OF PRACTICE FOR LICENSED EMERGENCY MEDICAL SERVICES PERSONNEL:

A. Medical director means a physician functioning as the service EMS medical director as defined and described in 7.27.3 NMAC, medical direction for emergency medical services. Medical control means supervision provided by or under the direction of a physician.

B. Prior to approving a new skill, technique, medication, or procedure, it shall be documented by the service director, medical director, or approved EMS training institution that the EMS provider has been appropriately trained to perform those new skills, techniques, medications, or procedures.

C. Service medical director approved: All service medical director approved skills, techniques, medications, or procedures are considered advanced life support. Prior to utilizing any skill, technique, medication or procedure designated as service medical director approved, it shall be documented by the service director, medical director, or approved EMS training institution that the EMS provider has been appropriately trained to administer the medications or perform the skills, techniques, medications or procedures. Additionally, each EMS provider must have a signed authorization from the service's medical director on file at the EMS service's headquarters or administrative offices.

D. Any device in an EMS agency's treatment guideline/protocol designed and utilized to facilitate successful completion of a skill or other treatment modality, including but not limited to cardiopulmonary resuscitation (CPR) devices, intraosseous placement devices, and positive pressure ventilation devices, must be approved by the service medical director.

E. Wilderness protocols: The following skills shall only be used by providers who have a current wilderness certification from a bureau approved wilderness caregiver course, who are functioning in a wilderness environment as a wilderness provider (an environment in which time to a hospital is expected to exceed two hours, except in the case of an anaphylactic reaction, in which no minimum transport time is required), and are authorized by their medical director to provide the treatment:

- (1) minor wound cleaning and management;
- (2) cessation of CPR;
- (3) field clearance of the cervical-spine;
- (4) reduction of dislocations resulting from indirect force of the patella, digit, and anterior

shoulder.

F.

Community emergency medical services and mobile integrated health programs:

Community EMS (CEMS) and mobile integrated health (MIH) programs shall be provided by EMS caregivers who, after completing a bureau approved [community EMS]CEMS/MIH caregiver course, are functioning as part of a [community emergency medical services] program that has been reviewed and approved by the EMS bureau. The providers must be authorized by their medical director to perform the skills listed in their application as part of the [community EMS]] program. These programs may include referrals that involve transport to non-hospital locations, and for non-transport decisions. Skills and interventions may include any of the approved skills and interventions for the appropriate level; any skill that exceeds the scope of practice must be approved through the special skill process. Skills may include, but are not limited to:

(1) education of patients in self-medication administration, and assessment of compliance with physician recommendations for health conditions;

(2) assessments for preventing falls and other sources of injury by identifying risks in patient

- (3) provide education on disease prevention;
- (4) administering immunizations;

(5) in collaboration with a healthcare team, assist in developing a care plan, and educate the patient in following the care plan;

(6) perform in home patient assessments commensurate with level of education and licensure and facilitate telemedicine clinician contact if available in order to provide information to a care team as to the progress or condition of a patient receiving therapies for medical conditions;

(7) provide assistance in locating and contacting appropriate providers of needed social

necessary;

services;

homes;

(8) treat discovered acute healthcare issues, transporting to emergency department if

(9) for chronic and non-acute issues, confirmed with online medical direction and agreed to by the patient, options other than EMS transport may be considered, including:

(a) arrange for non-emergent and non-EMS transportation to and care at an appropriate facility, such as a physician's office or urgent care center;

(b) provide referral information and arrange for follow up by appropriate care team members or social service personnel.

(10) assist with ongoing prescribed wound care.

G. Critical Care Transport services skills: Paramedic critical care transport skills shall be used only by paramedic providers who have successfully completed a bureau approved critical care transport paramedic or critical care flight paramedic course. Subsequent to completing the approved course, the critical care paramedic must successfully complete a bureau administered or approved third party exam within one year. Additionally, the paramedics shall be functioning as part of a ground or air EMS agency with an approved critical care transport special skill and authorized by the agency medical director to utilize these skills. Critical care transport program skills are only authorized for use during inter-facility critical care transport activities, with the exception of air ambulance agencies providing emergency scene response; or ground critical care transport special skills and medications that may be administered include, but are not limited to any of the below skills and medications; service specific skills and medication requests must be listed on the EMS agency critical care transport special skill application completed per 7.27.11.10 NMAC:

(1) monitoring of infusions including but not limited to anti-arrhythmics, nitrates, vasopressors, blood products, thrombolytics, sedation, pain management and antihypertensive medications that have required titration within the past two hours and may need to have their dosages adjusted during transport;

(2) performance of skills not listed in the paramedic scope of practice, such as but not limited to escharotomy, fasciotomy, insertion of chest tubes, pericardiocentesis, blood administration, and nerve blocks; administration of medications, initiation of infusions, and utilization of routes, not listed on the paramedic scope but requested in the EMS agency's special skill application and approved by the medical direction committee and EMS bureau;

(3) utilization of advanced patient monitoring, such as invasive hemodynamic monitoring via monitoring of central venous pressure, pulmonary artery pressure, intracranial pressure monitoring, Swan-Ganz catheters, arterial lines, fetal monitoring, point of care lab values, and other monitoring or tests not listed in the paramedic scope, but requested in the EMS agency's special skill application and approved by the medical direction committee and EMS Bureau;

(4) utilization of intensive care unit (ICU) level ventilator support, to include ventilators delivering positive end expiratory pressure, with multiple adjustable mode and setting parameters that include inspiratory plateau pressures, pressure regulated volume control, pressure support ventilation, pressure control ventilation, airway pressure release ventilation and others; also, any ventilator delivering a mixture of nitric oxide or other beneficial gas mixtures;

(5) transport of patients with intra-aortic balloon pump, temporary internal cardiac pacing, left ventricular assist device or a bi-ventricular assist device and other appropriate devices to address hemodynamic instability as requested in the EMS agency's special skill application and approved by the medical direction committee and EMS bureau;

(6) administer paralytics and sedatives to maintain airway control previously initiated, and administer and perform rapid sequence airway pharmacology and techniques in order to secure an airway in response to patient condition, as requested in the EMS agency's special skill application and approved by the medical direction committee and EMS bureau;

(7) pediatric intubation or endotracheal tube management as requested in the EMS agency's special skill application and approved by the medical direction committee and EMS bureau.

H. Utilization of pharmacological agents for the primary purpose of sedation, induction, or muscle relaxation to facilitate placement of an advanced airway requires medical direction committee special skills approval.

I. Over the counter (OTC) medications and products: A physician medical director may approve a list of over the counter (OTC) medications and products (i.e. NSAID's, antihistamines, anti-diarrheal, laxatives, antacids, vitamin supplements, hygiene products and other products) for distribution by an EMS caregiver working under medical direction to a requesting individual during scheduled stand-by situations. Examples are long-term wildfire responses, public events (concerts, rodeos, etc), various industry situations such as movie production and ski patrol, long-term construction & manufacturing projects, long-term search and rescue or tactical operations, and other situations where scheduled stand-by EMS is provided.

(1) The OTC medication/product must be properly labeled in individual dose packaging when distributed to the patient. Distribution from a bulk or multi-dose container is not permitted by this scope of practice, as well as other state and federal laws and regulations; medications will be distributed per manufacturer recommendations and labeling directions.

(2) The agency/EMS caregiver will maintain a written guideline that contains the list of physician approved OTC medications/products and the conditions for which they may be distributed. Specific dosing information and indications for pediatric patients must be included.

(3) The EMS agency/EMS caregiver must develop a method of documentation for the appropriate distribution of the OTC medications/products. This documentation shall include the OTC medication documentation and appropriate patient care report, per 7.27.10.12 NMAC (records and data collection) and 7.27.11.11 NMAC. Public regulation commission (PRC) certified ambulance agencies shall complete patient care documentation per 18.3.14.24 NMAC.

(4) OTC medications/products are distributed for the patient's self-administration and use. EMS caregivers will not administer OTC medications/products, unless approved elsewhere in the scope of practice for specific EMS patient care situations.

J. Licensed emergency medical dispatcher: (EMD).

(1) Medical direction is required for all items in the EMD scope of practice.

(2) The following allowable skills may be performed by EMDs who are licensed by the EMS bureau and functioning with an EMS bureau certified New Mexico emergency medical dispatch agency utilizing protocols and any EMD priority reference system approved by the EMS bureau and service medical director.

(a) Process calls for medical assistance in a standardized manner, eliciting required information for evaluating, advising, and treating sick or injured individuals, and dispatching an appropriate EMS response.

(b) Provide pre-arrival instructions to the patient through the caller when possible and appropriate to do so while functioning in compliance with an emergency medical dispatch priority reference system (EMDPRS).

K. EMS first responders (EMSFR):

(1) The following allowed drugs may be administered and skills and procedures may be performed without medical direction:

- (a) basic airway management;
- (b) use of basic adjunctive airway equipment;
- (c) suctioning;
- (d) cardiopulmonary resuscitation, according to current ECC guidelines;
- (e) obstructed airway management;
- (f) bleeding control via direct pressure and appropriate tourniquet use;
- (g) [spine immobilization]spinal motion restriction;
- (h) splinting (does not include femoral traction splinting);
- (i) scene assessment, triage, scene safety;
- (j) use of statewide EMS communications system;
- (k) emergency childbirth;

- (l) glucometry;
- (m) oxygen;
- (n) other non-invasive procedures as taught in first responder courses adhering to
- United States Department of Transportation curricula.

(b)

(2)

The following require service medical director approval:

(a) allowable skills:

(i) mechanical positive pressure ventilation utilizing a device that may have controls for rate, tidal volume, FiO2, and pressure relief/alarm and does not have multiple automatic ventilation modes; this skill includes devices that provide non-invasive positive pressure ventilation via continuous positive airway pressure (CPAP);

(ii) application and use of semi-automatic defibrillators, including cardiac rhythm acquisition for ALS caregiver interpretation or transmission to a care facility; this includes multi-lead documentation;

- (iii) hemostatic dressings for control of bleeding;
- (iv) insertion of laryngeal and supraglottic airway devices (examples: king airway, LMA), excluding multi-lumen airways).
 - administration of approved medications via the following routes:
 - (i) nebulized inhalation;
 - (ii) nasal mucosal atomization (MA);
 - (iii) intramuscular <u>or subcutaneous;</u>
 - (iv) oral (PO).
 - (c) allowable drugs:
 - (i) oral glucose preparations;
 - (ii) aspirin PO for adults with suspected cardiac chest pain;
 - (iii) atropine and pralidoxime via IM auto-injection for treatment of

chemical or nerve agent exposure;

- (iv) albuterol (including isomers) via inhaled administration;
- (v) naloxone via nasal mucosal atomizer;
- (vi) epinephrine[-via auto-injection device], 1:1000, no single dose greater

than 0.3 ml, subcutaneous or intramuscular injection with a pre-measured syringe (including autoinjector) or 0.3 ml TB syringe for anaphylaxis or status asthmaticus refractory to other treatments.

- (d) patient's own medication that may be administered:
 - (i) bronchodilators using pre-measured or metered dose inhalation device;
 - (ii) naloxone, if provided with a nasal MA or IM delivery system.
- L. EMT-BASIC (EMT-B):

(1) The following allowed drugs may be administered and skills and procedures may be performed without medical direction:

- (a) basic airway management;
- (b) use of basic adjunctive airway equipment;
- (c) suctioning;
- (d) cardiopulmonary resuscitation, according to current ECC guidelines;
- (e) obstructed airway management;
- (f) bleeding control to include appropriate tourniquet usage;
- (g) [spine immobilization]spinal motion restriction;
- (h) splinting;
- (i) scene assessment, triage, scene safety;
- (j) use of statewide EMS communications system;
- (k) childbirth (imminent delivery);
- (I) glucometry;
- (m) oxygen;
- (n) other non-invasive procedures as taught in EMT-B courses adhering to DOT

curricula;

(0) wound management.

The following require service medical director approval:

- (a) allowable skills:
 - (i) mechanical positive pressure ventilation utilizing a device that may

(2)

have controls for rate, tidal volume, fraction of inspired oxygen (FiO₂) and pressure relief/alarm and does not have multiple automatic ventilation modes; this skill includes devices that provide non-invasive positive pressure ventilation via continuous positive airway pressure (CPAP);

(ii) use of multi-lumen, supraglottic, and laryngeal airway devices (examples: PTLA, combi-tube, king airway, LMA) to include gastric suctioning;

(iii) application and use of semi-automatic defibrillators, including cardiac rhythm acquisition for ALS caregiver interpretation or transmission to a care facility; this includes multi-lead documentation;

(iv) acupressure;

(v) transport of patients with [naso]gastric tubes, urinary catheters,

heparin/saline locks, PEG tubes, or vascular access devices intended for outpatient use;

(vi) performing point of care testing; examples include serum lactate values, cardiac enzymes, electrolytes, and other diagnostic values;

(vii) hemostatic dressings for control of bleeding.

- (b) administration of approved medications via the following routes:
 - (i) nebulized inhalation;
 - (ii) subcutaneous;
 - (iii) intramuscular;
 - (iv) nasal mucosal atomization (MA);
 - (v) oral (PO);
 - (vi) intradermal.
- (c) allowable drugs:
 - (i) oral glucose preparations;
 - (ii) aspirin PO for adults with suspected cardiac chest pain;
 - (iii) activated charcoal PO;
 - (iv) acetaminophen PO[-in pediatric patients with fever];
 - (v) atropine and pralidoxime via IM autoinjection for treatment of

chemical or nerve agent exposure.

- (vi) albuterol (including isomers), via inhaled administration;
- (vii) ibuprofen PO in pediatric or adults to treat fever or pain;
- (viii) ipratropium, via inhaled administration, in combination with or after

albuterol administration;

(ix) naloxone by SQ, IM, or IN route;

(x) epinephrine, 1:1000, no single dose greater than 0.3 ml, subcutaneous

or intramuscular injection with a pre-measured syringe (including autoinjector) or 0.3 ml TB syringe for anaphylaxis or status asthmaticus refractory to other treatments.

- (d) patient's own medication that may be administered:
 - (i) bronchodilators using pre-measured or metered dose inhalation device;(ii) sublingual nitroglycerin for unrelieved chest pain, with on line medical

control only;

i) submigual introgrycerin for unreneved enest pain, with on internetical

(iii) situations may arise involving patients with uncommon conditions requiring specific out of hospital administered medications or procedures; family members or the designated caregiver trained and knowledgeable of the special needs of the patient should be recognized as the expert regarding the care of the patient; EMS can offer assistance in airway management appropriate to their level of licensure, and administer the patient's prescribed medications where appropriate only if the medication is in the EMS provider's scope of practice; EMS services are not expected to provide the prescribed medications for these special needs patients.

(3) Immunizations and biologicals: Administration of immunizations, vaccines, biologicals, and TB skin testing is authorized under the following circumstances:

(a) to the general public as part of a department of health initiative or emergency response, utilizing department of health protocols; the administration of immunizations is to be under the supervision of a physician, nurse, or other authorized health provider;

(b) TB skin tests may be applied and interpreted if the licensed provider has successfully completed required department of health training;

(c) in the event of a disaster or emergency, the state EMS medical director or chief medical officer of the department of health may temporarily authorize the administration of pharmaceuticals or tests

not listed above.

M. **EMT-INTERMEDIATE (EMT-I):**

The following allowed drugs may be administered and skills and procedures may be (1) performed without medical direction:

- basic airway management; **(a)**
- use of basic adjunctive airway equipment; **(b)**
- (c) suctioning:
- cardiopulmonary resuscitation, according to ECC guidelines; (d)
- obstructed airway management; (e)
- bleeding control including appropriate use of tourniquet; **(f)**
- [spine immobilization]spinal motion restriction; (g)
- splinting; (h)
- scene assessment, triage, scene safety; (i)
- use of statewide EMS communications system; (j)
- childbirth (imminent delivery); (k)
- **(D**) glucometry;
- (m)oxygen;

(a)

- (n) wound management.
- (2) The following require service medical director approval:
 - allowable skills:

mechanical positive pressure ventilation utilizing a device that may (i) have controls for rate, tidal volume, FiO2, and pressure relief/alarm and does not have multiple automatic ventilation modes; this skill includes devices that provide non-invasive positive pressure ventilation via continuous positive airway pressure (CPAP);

- (ii)
- use of multi-lumen, supraglottic, and laryngeal airway devices (examples: PTLA, combi-tube, king airway, LMA) to include gastric suctioning;

application and use of semi-automatic defibrillators, including cardiac (iii) rhythm acquisition for ALS caregiver interpretation or transmission to a care facility; this includes multi-lead documentation;

- (iv) acupressure;
- transport of patients with [naso]gastric tubes, urinary catheters, (v)

heparin/saline locks, PEG tubes, or vascular access devices intended for outpatient use;

- (vi) peripheral venous puncture/access;
- (vii) blood drawing;
- (viii) pediatric intraosseous tibial access;
- (ix) adult intraosseous access;
- point of care testing; examples include serum lactate values, cardiac **(x)**

enzymes, electrolytes, and other diagnostic values;

- (xi) hemostatic dressings for control of bleeding.
- administration of approved medications via the following routes: **(b)**
 - intravenous; (i)
 - (ii) nasal mucosal atomization (MA);
 - nebulized inhalation; (iii)
 - sublingual; (iv)
 - (v) intradermal;
 - (vi) intraosseous;
- (vii) endotracheal (for administration of epinephrine only, under the direct

supervision of an EMT-paramedic, or if the EMS service has an approved special skill for endotracheal intubation);

- oral (PO); (viii)
- intramuscular; (ix)
- subcutaneous. **(x)**
- allowable drugs: (c)
 - oral glucose preparations; (i)
 - aspirin PO for adults with suspected cardiac chest pain; (ii)
 - activated charcoal PO; (iii)
 - acetaminophen[-PO in pediatric patients with fever]; (iv)

(v)ibuprofen PO to pediatrics and adults for pain or fever; IV or IM [with
online medical direction only]ketorolac for pain;
(vi)(vi)IM autoinjection of the following agents for treatment of chemical or

nerve agent exposure: atropine, pralidoxime; (vii) albuterol (including isomers) via inhaled administration;

(viii) ipratropium, via inhaled administration in combination with or after

albuterol administration;

- (ix) naloxone;
- (x) I.V. fluid therapy (except blood or blood products);
- (xi) dextrose;

(xii) epinephrine (1:1000), SQ or IM (including autoinjector) for

anaphylaxis and known asthmatics in severe respiratory distress (no single dose greater than 0.3 cc); (xiii) epinephrine (1:10,000) in pulseless cardiac arrest for both adult and

pediatric patients; epinephrine may be administered via the endotracheal tube in accordance with most current ACLS and PALS guidelines;

(xiv) nitroglycerin (sublingual); must have intravenous access established prior to administration or approval of online medical control if IV access is unavailable; (xv) morphine, fentanyl, or dilaudid for use in pain control with approval of

on-line or off-line (written protocol) medical control;

(e)

- (xvi) diphenhydramine for allergic reactions or dystonic reactions;
- (xvii) glucagon, to treat hypoglycemia in diabetic patients when intravenous

access is not obtainable;

- (xviii) anti-emetic agents, for use as an anti-emetic only;
- (xix) corticosteroids for respiratory illness or allergic reaction;
- (xx) hydroxycobalamine;

(xxi) lidocaine two percent, preservative and epinephrine free for IV use) for administration into the intraosseous space on pain responsive adult patients while receiving intraosseous fluids or medications.

(d) patient's own medication that may be administered:

- (i) bronchodilators using pre-measured or metered dose inhalation device;
- (ii) sublingual nitroglycerin for unrelieved chest pain; must have

intravenous access established prior to administration or approval of online medical control if IV access is unavailable;

(iii) glucagon;

(iv) situations may arise involving patients with uncommon conditions

requiring specific out of hospital administered medications or procedures; family members or the designated caregiver trained and knowledgeable of the special needs of the patient should be recognized as the expert regarding the care of the patient; EMS can offer assistance in airway management appropriate to their level of licensure, IV access, and the administration of the patient's prescribed medications where appropriate only if the medication is in the EMS provider's scope of practice; online (direct contact) medical control communication must be established with the medical control physician approving the intervention; EMS services are not expected to provide the prescribed medications for these special needs patients.

drugs allowed for monitoring during interfacility transport:

(i) potassium; intermediate EMT's may monitor IV solutions that contain potassium during transport (not to exceed 20 mEq/1000cc or more than 10 mEq/hour);

(ii) antibiotics and other anti-infectives utilizing an infusion pump; intermediate EMT's may monitor antibiotic or other anti-infective agents, provided a hospital initiated infusion has been running for a minimum of 30 minutes prior to the intermediate initiating the transfer, and the intermediate EMT is aware of reactions for which to monitor and the appropriate action to take before assuming responsibility for patient care.

(f) immunizations and biologicals: administration of immunizations, vaccines, biologicals, and TB skin testing is authorized under the following circumstances:

(i) to the general public as part of a department of health initiative or emergency response, utilizing department of health protocols; the administration of immunizations is to be under the supervision of a physician, nurse, or other authorized health provider;

(ii) administer vaccines to EMS and public safety personnel;

(iii) TB skin tests may be applied and interpreted if the licensed provider has successfully completed required department of health training;

(iv) in the event of a disaster or emergency, the state EMS medical director or chief medical officer of the department of health may temporarily authorize the administration of pharmaceuticals or tests not listed above.

N. EMT-PARAMEDIC (EMT-P):

(1) The following allowed drugs may be administered and skills and procedures may be performed without medical direction:

- (a) basic airway management;
- (b) use of basic adjunctive airway equipment;
- (c) suctioning;
- (d) cardiopulmonary resuscitation, according to current ECC guidelines;
- (e) obstructed airway management;
- (f) bleeding control including the appropriate use of tourniquet;
- (g) [spine immobilization]spinal motion restriction;
- (h) splinting;
- (i) scene assessment, triage, scene safety;
- (j) use of statewide EMS communications system;
- (k) childbirth (imminent delivery);
- (I) glucometry;
- (m) oxygen;

(a)

(2)

- (n) wound management.
- The following require service medical director approval:
 - allowable skills:

(i) mechanical positive pressure ventilation utilizing a device that may have controls for rate, tidal volume, FiO2, and pressure relief/alarm and has multiple automatic ventilation modes; this skill includes devices that provide non-invasive positive pressure ventilation (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BPAP);

(ii) use of multi-lumen, supraglottic, and laryngeal airway devices (examples: PTLA, combi-tube, king airway, LMA) to include gastric suctioning;

(iii) transport of patients with [naso]gastric tubes, urinary catheters,

heparin/saline locks, PEG tubes, or vascular access devices[-intended for outpatient use];

- (iv) application and use of semi-automatic defibrillators;
- (v) acupressure;
- (vi) peripheral venous puncture/access;
- (vii) blood drawing;
- (viii) I.V. fluid therapy;

(ix) direct laryngoscopy for endotracheal intubation and removal of foreign body in patients 13 and older; for patients 12 and under, for removal of foreign body only;

- (x) endotracheal intubation for patients over the age of 12;
- (xi) thoracic decompression (needle thoracostomy);
- (xii) surgical cricothyroidotomy;
- (xiii) insertion of [naso]gastric tubes;
- (xiv) cardioversion and manual defibrillation;
- (xv) external cardiac pacing;
- (xvi) cardiac monitoring;
- (xvii) use of infusion pumps;
- (xviii) initiation of blood and blood products with on-line medical control;
- (xix) intraosseous access;
- (xx) performing point of care testing; examples include serum lactate

values, cardiac enzymes, electrolytes, and other diagnostic values;

- (xxi) hemostatic dressings for control of bleeding;
- (xxii) vagal maneuvers.
- (b) administration of approved medications via the following routes:
 - (i) intravenous;
 - (ii) nasal mucosal atomization (MA);

<pre>(ii) nebulized inhalation; iv) sublingual; vi) intradsermal; vi) intradsermal; vii) intrassecous; viii) endotracheal; viii) oral (PO); viii) endotracheal; viii) viii) oral (PO); viii) oral (PO); viii) subcutaneous. viii) subcutaneous. viii) activated charcoal; viii) activated charcoal; viii) activated charcoal; viii) activated charcoal; viii) activated charcoal; vi) albuterol (including isomers); vi) agnorin; vi) agnorin; vii) attorpium; vii) attorpium; viii) diptenlydaramine; viii) diptenlydaramine; viii) diptenlydaramine; viii) inpatropium; viii) inpatropium; viii) inpatropium; viii) ingalycein; viii) nacotone; viii) nacotone; viii) nacotone; viii) nacotorie analgesies; viii) nacotorie analgesies; viii) nacotorie analgesies; viii) nacotorie; viii) penviephrine neasl spray; viii) penviephrine neasl spray; viiii) viii viiii viiii viiiii viiiiiiii</pre>		
(iv)sublingual;(v)intradermal;(vii)intradermal;(viii)endotracheal;(viii)ord (PO);(xi)intranuscular;(xi)topical;(xi)rectal;(xii)rectal;(xiii)subcutaneous.(viii)acetaminophen;(iii)acetaminophen;(iii)acetaminophen;(iii)acetaminophen;(iii)acetaminophen;(iii)acetaminophen;(vi)abbuteof (including isomers);(vi)abbuteof (including isomers);(vi)abbuteof (including isomers);(vi)aubateol (including isomers);(vii)atopine sulfate;(viii)atopine sulfate;(viii)atopine sulfate;(viii)dextrose;(xi)calcium preparations;(xi)calcium preparations;(xii)dextrose;(xiii)diptenhydramine;(xiii)diptenhydramine;(xiii)diptenhydramine;(xiii)iptratepium;(xiii)iptratepium;(xiii)introdice analgesics;(xiii)introdice analgesics;(xiii)narcotic analgesics;(xiii)ipratepium;(xiii)pratepium;(xiii)pratepium;(xiii)pratepium;(xiii)pratepium;(xiii)pratepium;(xiii)pratepium sulfate;(xiii)iptratepium;(xii	(iii)	nebulized inhalation:
(v) intradermal; (vi) intraosseous; (vii) endotracheal; (viii) oral (PO); (ix) intramscular; (x) topical; (xii) intramscular; (xii) topical; (xiii) IV drip; (xiii) allowable drugs; (i) actaminophen; (ii) actaminophen; (iii) adenosine; (vi) abuterol (including isomers); (v) abiterol (including isomers); (v) abuterol (including isomers); (vi) abuterol (including isomers); (vii) benzoiazepines; (viii) benzoiazepines; (viii) benzoiazepines; (xiv) epinephrine; (xiv) epinephrine; (xiv) iglucagon; (xix) indocane;		
(vi) intracesseous; (vii) endotracheal; (viii) oral (PO); (xi) intramuscular; (xi) topical; (xi) retramuscular; (xii) actaminophen; (ii) actaminophen; (iii) actaminophen; (iii) actaminophen; (iii) actaminophen; (vi) albuteol (including isomers); (v) amiodarone; (vi) albuteol (including isomers); (vi) albuteol (including isomers); (vii) albuteol (including isomers); (vii) albuteol (including isomers); (vii) albuteol (including isomers); (vii) albuteol (including isomers); (viii) alputeodizepines; (xii) calcium preparations; (xii) calcium preparat		
(vii)endotracheal;(viii)oral (PO);(ix)intranuscular;(x)topical;(xi)rectal;(xii)iv drip;(xiii)iv drip;(xiii)alourable druggs:(c)allourable druggs:(i)activated charcoal;(iii)activated charcoal;(iii)adonsine;(iv)albuterol (including isomers);(v)amiodarone;(vi)aspirin;(vi)aspirin;(vii)atropications;(xii)calcium preparations;(xii)calcium preparations;(xii)dextrose;(xiii)glucagon;(xiii)iphenhydramine;(xiv)glucagon;(xiv)ipmephrine;(xiv)ipmephrine;(xiv)ipmephrine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)glucagon;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenhydramine;(xiv)iphenkine asal spray;(xvi)introducerni;(xvii)intraducerni;(xvii)intraducerni;(xviii)iphenkine; asal spray;(xviii)iphenkine; asal spray;(xviii)iphenkine; asal spray;(xviii)iphenkine; asal spray; <th></th> <th></th>		
(viii) ord (PO); (ix) intramuscular; (x) topical; (xi) rectal; (xii) subcutaneous. (xiii) subcutaneous. (x) allowable drugs; (xiii) actaminophen; (xiii) actaminophen; (ii) activated charcoal; (iii) activated charcoal; (iv) albuterol (including isomers); (v) amiodarone; (v) aniodarone; (vii) atropine sulfate; (viii) benzodiazepines; (xi) calcium preparations; (x) calcium preparations; (xi) endocase; (xiii) diphenhydramine; (xiii) dipueagon; (xviii) ipartopium; (xiii) ipartopium; (xiii) indocane; (xviii) naloxone; (xviii) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxii) (xxiii) nonsteroidal anti-inflammatory drugs (
(ix) intramuscular; (x) inpical; (x) ropical; (xii) IV drip; (xiii) stoutaneous. (c) allowable drugs; (i) acetaminophen; (ii) activated charcoal; (iii) adenosine; (iv) albuterol (including isomers); (v) abbuerol (including isomers); (v) abbuerol (including isomers); (viii) bapterol (including isomers); (viii) activated charcoal; (iii) adenosine; (viii) bapterol (including isomers); (vi) aspirin; (viii) bapterol (including isomers); (xvii) periodiazepines; (xvii) piratopiuma; (xvii) piratopiuma;		
(x) topical; (xi) rectal; (xii) IV drip; (xiii) subcutaneous. (c) allowable drugs: (i) acetaminophen; (ii) acitvated charcool; (iii) activated charcool; (iii) activated charcool; (iv) albuterol (including isomers); (v) aspirin; (vi) aspirin; (vii) atropine sulfate; (vii) atropine sulfate; (xii) calcium preparations; (xi) calcium preparations; (xi) calcium preparations; (xii) diversore; (xiii) diphenhydramine; (xiv) glucagon; (xvi) glucagon; (xviii) ipratropium; (xxiii) naloxone; (xxiii) naloxone; (xxiii) naloxone; (xxiii) oxylocin; (xxiii) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; ixxiii		
(xi) rcital; (xii) IV drip; (xiii) subcutaneous. (c) allowable drugs: (i) acetaminophen; (ii) acetaminophen; (iii) activated charcoal; (iii) adenosine; (iv) abuterol (including isomers); (v) amiodarone; (v) amiodarone; (viii) atopine sulfate; (viii) atopine sulfate; (viii) atopine sulfate; (viii) atopine sulfate; (viii) dectrose; (xii) dectrose; (xii) dectrose; (xiii) diptenhydramine; (xiv) epinephrine; (xvi) flucagon; (xvii) hydroxycobalamine; (xvii) hydroxycobalamine; (xvii) indoxone; (xvii) naloxone; (xvii) naloxone; (xvii) naloxone; (xvii) naloxone; (xvii) naloxone; (xvii)		
(xii) IV drip; (xiii) subcutaneous. (c) allowable drugs: (i) acetaminophen; (ii) acetaminophen; (iii) activated charcoal; (iii) adenosine; (iv) albuterol (including isomers); (v) amiodarone; (vi) aspirin; (vii) batzodiazepines; (iii) calcium preparations; (viii) batzodiazepines; (ix) coticosteroids; (xii) diphenhydramine; (xiii) diphenhydramine; (xiv) glucagon; (xiv) glucagon; (xiv) foloacine; (xiv) idocaine; (xiv) idocaine; (xiv) intoglycerin; (xiii) natrootic analgesics; (xiii) introglycerin; (xiv) oral glucose preparations; (xiv) oxytocin; (xivi) parliedxime, IM auto-injection for treatment of chemical and nerve agent exposure; xixi) anti-metic agent		
(viii) subcuriancous. (c) allowable drugs: (i) activatel charcoal; (ii) activatel charcoal; (iii) activatel charcoal; (iii) activatel charcoal; (iii) adenosine; (v) abuterol (including isomers); (vi) abuterol (including isomers); (vi) astropine sulfate; (vii) benzodiazepines; (viii) benzodiazepines; (vii) corticosteroids; (x) corticosteroids; (x) corticosteroids; (xi) dectrose; (xii) glucagon; (xii) glucagon; (xiii) ipratropium; (xiii) ipratropium; (xiii) inacotic analgesics; (xiii) inacotic analgesics; (xiii) nalcosne; (xiii) orticose preparations; (xiii) interofic analgesics; (xiii) interofic analgesics; (xiii) nalcosne; (xiiii) orticose preparations;		
(c)allowabbe drugs:(i)acetaminophen;(ii)acetaminophen;(iii)adenosine;(iv)abuero! (including isomers);(v)abuero! (including isomers);(v)amiodarone;(vi)aspirin;(vii)atopirones;(vii)atopirones;(viii)benzodiazepines;(viii)benzodiazepines;(vii)destrose;(xii)destrose;(xiii)diphenhydramine;(xiv)epinephrine;(xvi)glucagon;(xvii)ipyacebalamine;(xvii)ipyacebalamine;(xvii)ipyacebalamine;(xvii)ipyacebalamine;(xviii)ipyatropium;(xix)naloxone;(xxi)naloxone;(xxii)naloxone;(xxii)naloxone;(xxii)naloxone;(xxii)narcotic analgesics;(xxii)naloxone;(xxii)narcotic analgesics;(xxii)narcotic analgesics;(xxiii)phenylephrine nasal spray;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations;(xxviii)pralexopations; <t< th=""><th></th><th></th></t<>		
 (i) acetaminophen; (ii) activated charcoal; (iii) adenosine; (iv) albuterol (including isomers); (v) amiodarone; (v) aspirin; (vi) atropine sulfate; (vii) benzodiazepines; (viii) benzodiazepines; (viii) corticosteroids; (x) corticosteroids; (xi) corticosteroids; (xi) dextrose; (xii) diphenhydramine; (xv) punephrine; (xv) glucagon; (xviii) diphenhydramine; (xvi) glucagon; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) narcotic analgesics; (xxii) narcotic analgesics; (xxii) narcotic analgesics; (xxii) narcotic agents, (xvi) oxytocin; (xvi) phenlphrine nasal spray; (xvi) phenlphrine nasal spray; (xxvi) phenlphrine is a san anti-emetic only; (xxii) toica anesthetic ophthalmic solutions; (xxxi) thiamine; (xxxi) thiamine; (xxxi) thiamine; (xxxii) toica anesthetic ophthalmic solutions; (xxxii) tranzenic acid; for patients >15 years of age, bolus of 1000 mg in 259 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. 		
 (ii) activated charcoal; (iii) adenosine; (iii) advience; (iii) and conce; (iii) aspirin; (v) aspirin; (vi) aspirin; (vii) atropine sulfate; (viii) benzodiazepines; (viii) benzodiazepines; (viii) costeroids; (xi) costeroids; (xi) dextrose; (xii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xv) furosemide; (xvi) glucagon; (xvi) inpartopium; (xvi) inpartopium; (xvi) inpartopium; (xvi) inpartopium; (xvi) manesium sulfate; (xvi) naloxone; (xvi) naloxone; (xvi) naloxone; (xvi) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult 		
<pre>(iii) adenosine; (iv) albuterol (including isomers); (v) amiodarone; (vi) aspirin; (vii) aspirin; (viii) benzodiazepines; (viii) benzodiazepines; (viii) calcium preparations; (v) corticosteroids; (vi) dextrose; (vii) dextrose; (viii) diphenhydramine; (vii) dextrose; (viii) diphenhydramine; (vii) epinephrine; (vv) furosemide; (vv) glucagon; (vvi) glucagon; (vvi) glucagon; (vvi) glucagon; (vvii) hydroxycobalamine; (vvi) glucagon; (vviii) ipratropium; (vvi) iptaropium; (vvi) idocaine; (vviii) ipratropium; (vviii) ipratropium; (vviii) inarcotic analgesics; (vxiii) nalcotone; (vxiii) natroctic analgesics; (vxiii) natroctic analgesics; (vxiii) natroctic analgesics; (vxiii) natroctic analgesics; (vxiii) natroctic analgesics; (vxiii) phenylephrine nasal spray; (vxviii) pratidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (vxiv) oxytocin; (vxvi) phenylephrine nasal spray; (vxvii) pratidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (vxiv) anti-emetic agents, for use as an anti-emetic only; (vxx) sodium bicarbonate; (vxxii) thiamine; (vxxii) tranexamic acid: for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(vxxiii) xxxy intravenous fluids.</pre>		
(iv) albuterol (including isomers); (v) amiodarone; (vi) aspirin; (vii) atropine sulfate; (viii) benzodiazepines; (ix) calcium preparations; (x) corticosteroids; (xi) dextrose; (xii) diphenhydramine; (xii) diphenhydramine; (xii) diphenhydramine; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiii) glucagon; (xvi) glucagon; (xvii) glucagon; (xviii) iphacyobalamine; (xviii) ipalcoxone; (xxii) naloxone; (xxii) naloxone; (xxii) naloxone; (xxiii) narcotic analgesics; (xxiii) naloxone; (xxiii) naloxone; (xxiii) naloxone; (xxiiii) naloxone; <th></th> <th></th>		
(v) amiodarone; (vi) aspirin; (vii) aspirin; (viii) benzodiazepines; (viii) benzodiazepines; (viii) calcium preparations; (x) calcium preparations; (x) calcium preparations; (x) corticosteroids; (xi) dextrose; (xiii) dextrose; (xiii) dextrose; (xiv) epinephrine; (xv) glucagon; (xvi) glucagon; (xvi) glucagon; (xvi) glucagon; (xvi) indocane; (xvi) naloxone; (xxi) naloxone; (xxi) naloxone; (xxii) narcotic analgesics; (xxii) naitosone; (xxii) narcotic analgesics; (xxiii) naloxone;		
(vi) aspirin; (vii) atropine sulfate; (viii) benzodiazepines; (viii) benzodiazepines; (viii) calcium preparations; (x) corticosteroids; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xvii) hydroxycobalamine; (xvii) hydroxycobalamine; (xvii) hydroxycobalamine; (xvii) ipatentpium; (xix) lidocaine; (xvi) naloxone; (xxii) naloxone; (xxii) narcotic analgesics; (xxiii) narcotic analgesics; (xxiii) norsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xv) (xvii) phrylephrine nasal spray; (xxvii) phrylephrine nasal spray; (xxviii) praledoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxi) (xxxii) p		
(vii) atropine sulfate; (viii) benzodiazepines; (ix) calcium preparations; (x) corticosteroids; (xi) dextrose; (xiii) diphenhydramine; (xiv) epinephrine; (xvi) glucagon; (xvii) glucagon; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) hydroxycobalamine; (xviii) ipatropium; (xix) naloxone; (xxii) naloxone; (xxii) narcotic analgesics; (xxiii) nitroglycerin; (xxiii) nitroglycerin; (xxvii) oral glucose preparations; (xxvii) prelichts with pain or fever; (xxviii) prelidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi)		
(viii) benzodiazepines; (ix) calcium preparations; (x) corticosteroids; (xi) dextrose; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xviii) hydroxycobalamine; (xviii) ipratropium; (xix) hydroxycobalamine; (xvii) ipratropium; (xix) magnesium sulfate; (xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxii) narcotic analgesics; (xxii) norsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxvi) (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine;		
<pre>(ix) calcium preparations; (x) corticosteroids; (xi) dextrose; (xii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xv) glucagon; (xvi) glucagon; (xvii) hydroxycobalamine; (xvii) ipratropium; (xix) lidocaine; (xx) magnesium sulfate; (xx) magnesium sulfate; (xx) magnesium sulfate; (xxii) naloxone; (xxii) narcotic analgesics; (xxiii) phenylephrine nasal spray; (xxviii) prelidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxii) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxiii) trait-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiii) trait-emetic agents; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(********) ****************************</pre>		
(x) corticosteroids; (xi) dextrose; (xiii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xviii) hydroxycobalamine; (xxii) hadoxone; (xxi) maloxone; (xxii) naloxone; (xxii) naloxone; (xxii) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxiv) (xxvi) oral glucose preparations; (xxvi) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) sodium bicabonate; <tr< th=""><th></th><th></th></tr<>		
(xi) dextrose; (xiii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xvii) hydroxycobalamine; (xviii) ipartopium; (xix) lidocaine; (xix) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxii) narcotic analgesics; (xxii) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xvii) phylephrine nasal spray; (xxvii) phylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxix) anti-emetic agents, for use as an anti-emetic only; (xxxi) sodium bicarbonate; (xxxii) thia-ine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours.		
(xiii) diphenhydramine; (xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xvii) hydroxycobalamine; (xviii) ipartopium; (xviii) ipartopium; (xix) lidocaine; (xxi) naloxone; (xxii) naloxone; (xxii) narootic analgesics; (xxii) nortic analgesics; (xxiii) nortic analgesics; (xxiii) nortic analgesics; (xxiii) oxytocin; (xxvi) oxytocin; (xxviii) praidoxime, IM auto-injection for treatment of chemical and nerve agent exposure;		
(xiv) epinephrine; (xv) furosemide; (xvi) glucagon; (xviii) hydroxycobalamine; (xviii) ipatropium; (xix) lidocaine; (xx) magnesium sulfate; (xxi) naloxone; (xxii) naloxone; (xxiii) narcotic analgesics; (xxiii) narcotic analgesics; (xxiii) norsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oxytocin; (xxvii) patients, for use as an anti-emetic or adult patients with pain or fever; (xix) (xxvi) oxytocin; (xxvii) penylephrine nasal spray; (xxvii) patientic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)]xxiv		
(xv) furosemide; (xvi) glucagon; (xvii) hydroxycobalamine; (xviii) ipratropium; (xviii) ipratropium; (xxi) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxiii) narcotic analgesics; (xxiii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvi) oxytocin; (xxviii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxxi) anti-emetic agents, for use as an anti-emetic only; (xxxi) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiii) traexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline ove		
(xvi) glucagon; (xvii) hydroxycobalamine; (xviii) ipratropium; (xix) lidocaine; (xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxii) narcotic analgesics; (xxii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvi) oxytocin; (xxvii) phylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xix) (xxi) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophtalmic solutions; (xxxiii) trainexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxiii)] [(xxiii)] xxiv vasopressor agents; ((xxiii)) <t< th=""><th></th><th></th></t<>		
(xvii) hydroxycobalamine; (xviii) ipratropium; (xix) lidocaine; (xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxiii) nitroglycerin; (xxv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvi) oxytocin; (xvviii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxxi) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxii) topical anesthetic ophtalmic solutions; (xxxiii) topical anesthetic ophtalmic solutions; (xxxiii) topical anesthetic of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] (xxxy) vasopressor agents; [(xxxiii)] xxxy intravenous fluids.		
(xviii) ipratropium; (xix) lidocaine; (xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxiii) narcotic analgesics; (xxiii) nitroglycerin; (xxii) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxvii) phenylephrine nasal spray; (xxvii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxxi) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxii) thiamine; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiiii) topica		
(xix) lidocaine; (xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxiii) narcotic analgesics; (xxiii) nitroglycerin; (xxv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxxi) anti-emetic agents, for use as an anti-emetic only; (xxxi) sodium bicarbonate; (xxxii) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiii) topical anesthetic ophthalmic over 8 hours. [(xxiii)] tanexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 10000 mg in a liter of normal saline over 8 hours. [(xxiii)] xxiv vasopressor agents; [(xxiii)] intravenous fluids.		
(xx) magnesium sulfate; (xxi) naloxone; (xxii) narcotic analgesics; (xxiii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxv) oral glucose preparations; (xxvi) oxytocin; (xxviii) phenylephrine nasal spray; (xxviii) prelidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxiii) topical anesthetic ophthalmic solutions; (xxxiiii) topical anesthetic ophthalmic so		· ·
(xxi) naloxone; (xxii) narcotic analgesics; (xxiii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxviii) prelidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xix) (xxix) anti-emetic agents, for use as an anti-emetic only; (xxxi) sodium bicarbonate; (xxxii) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] yxxy intravenous fluids.		
(xxii) narcotic analgesics; (xxiii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) (xxvi) oral glucose preparations; (xxvi) oxytocin; (xxviii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xix) (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] vasopressor agents; [(xxxiii)] vasopressor agents; [(xxxiii)] intravenous fluids.		
<pre>(xxiii) nitroglycerin; (xxiv) nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adult patients with pain or fever; (xxv) oral glucose preparations; (xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)]xxxiv vasopressor agents; [(xxxiv)]xxxv intravenous fluids.</pre>		
(xxiv)nonsteroidal anti-inflammatory drugs (NSAIDS) to pediatric or adultpatients with pain or fever;(xxv)(xxv)oral glucose preparations;(xxvi)oxytocin;(xxvii)phenylephrine nasal spray;(xxviii)pralidoxime, IM auto-injection for treatment of chemical and nerveagent exposure;(xxix)(xxix)anti-emetic agents, for use as an anti-emetic only;(xxx)sodium bicarbonate;(xxxi)thiamine;(xxxii)topical anesthetic ophthalmic solutions;(xxxiii)tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours.[(xxxii)](xxxiv)(xxxii)intravenous fluids.		
patients with pain or fever; (xxv) oral glucose preparations; (xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxx) thiamine; (xxxii) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)]xxxiv vasopressor agents; [(xxxiv)]xxxv intravenous fluids.		C 1
(xxv) oral glucose preparations; (xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) (xxxi) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] xxxiv (xxxiv) vasopressor agents; [(xxxiv)] intravenous fluids.		
(xxvi) oxytocin; (xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] xxxiv vasopressor agents; [(xxxiv)] xxv intravenous fluids.		oral alucase preparations:
(xxvii) phenylephrine nasal spray; (xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] vasopressor agents; [(xxxiv)] intravenous fluids.		
(xxviii) pralidoxime, IM auto-injection for treatment of chemical and nerve agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] vasopressor agents; [(xxxiv)] intravenous fluids.		
agent exposure; (xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] xxxiv vasopressor agents; [(xxxiv)] xxv intravenous fluids.	(XXVII) (VVViii	prelidentime initial spray,
(xxix) anti-emetic agents, for use as an anti-emetic only; (xxx) sodium bicarbonate; (xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] [(xxxiii)] (xxxiv) vasopressor agents; [(xxxiv)] [xxxv intravenous fluids.		j prandoxinie, nu auto injection for treatment of chemical and herve
(xxx) sodium bicarbonate; (xxxi) thiamine; (xxxi) topical anesthetic ophthalmic solutions; (xxxii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)]xxxiv vasopressor agents; [(xxxiv)]xxxv intravenous fluids.		anti-emetic agents for use as an anti-emetic only.
(xxxi) thiamine; (xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] xxxiv vasopressor agents; [(xxxiv)] xxv intravenous fluids.		
(xxxii) topical anesthetic ophthalmic solutions; (xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)] xxxiv vasopressor agents; [(xxxiv)] intravenous fluids.		
(xxxiii) tranexamic acid; for patients >15 years of age, bolus of 1000 mg in 250 cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours. [(xxxiii)]xxxiv vasopressor agents; [(xxxiv)]xxxv intravenous fluids.		
<u>cc of normal saline over 10 minutes followed by 1000 mg in a liter of normal saline over 8 hours.</u> [(xxxiii)]xxxiv vasopressor agents; [(xxxiv)]xxxv intravenous fluids.		
[(xxxiii)] <u>xxxiv</u> vasopressor agents; [(xxxiv)] <u>xxxv</u> intravenous fluids.		
[(xxxiv)] <u>xxxv</u> intravenous fluids.		
	E (
(3) Drugs allowed for monitoring during inter-facility transports (initiated and		

(3) Drugs allowed for monitoring during inter-facility transports (initiated and administered by the sending facility with defined dosing parameters and requiring an infusion pump when given by continuous infusion unless otherwise specified); [the infusion may be terminated by the paramedic if appropriate, but if further adjustments are anticipated, appropriate hospital personnel should accompany the patient, or a critical eare transport unit should be utilized]any titration of one of these medications outside of the predefined dosing parameters requires online physician medical control:

⁽a) potassium (no infusion pump needed if concentration not greater than

20mEq/1000cc;

(b) anticoagulation type blood modifying agents (such as fibrolytic drugs, heparin, glycoprotein IIb-IIIa inhibitors/antagonists);

- (c) tranexamic acid (txa);
 - (d) procainamide;
 - (e) mannitol;
 - [(f)] [blood and blood products (no pump required);]
 - [(g)](f) aminophylline;
 - [(h)](g) antibiotics and other anti-infective agents;
 - [(i)](h) sodium nitroprusside;
 - [(j)](i) insulin;
 - [(k)](j) terbutaline;
 - [(1)](k) octreotide;
 - [(m)](l) nutritional supplements;
 - [(n)](m) beta blockers;
 - [(0)](n) calcium channel blockers;
 - (0) dobutamine
 - (p) nesiritide;
 - (q) propofol in patients that are intubated prior to transport;
 - (r) proton pump inhibitors and H2 antagonists;
 - (s) crotalidae polyvalent immune fab (ovine) ("crofab") [crofab] or anavip

<u>(crotalidae immune fab2 (equine)); either may be monitored during inter-facility transport provided the</u> [<u>physician]facility</u> initiated [<u>erofab</u>] infusion has been running for a minimum of 30 minutes prior to the paramedic initiating the transfer and assuming responsibility for patient care.

(4) **Immunizations and biologicals:** administration of immunizations, vaccines, biologicals, and TB skin testing is authorized under the following circumstances:

(a) to the general public as part of a department of health initiative or emergency response, utilizing department of health protocols; the administration of immunizations is to be under the supervision of a physician, nurse, or other authorized health provider;

(b) administer vaccines to EMS and public safety personnel;

(c) TB skin tests may be applied and interpreted if the licensed provider has successfully completed required department of health training;

(d) in the event of a disaster or emergency, the state EMS medical director or chief medical officer of the department of health may temporarily authorize the administration of other pharmaceuticals or tests not listed above.

(5) Skills approved for monitoring in transport:

- (a) internal cardiac pacing;
- (b) chest tubes.
- (6) Medications for administration during patient transfer:
 - (a) retavase (second dose only);
 - (b) protamine sulfate;

(c) non-depolarizing neuromuscular blocking agents in patients that are intubated

prior to transport;

(d) acetylcysteine.

(7) Patient's own medication that may be administered:

(a) epoprostenol sodium, treprostinil sodium, or other medications utilized for certain types of pulmonary hypertension;

(b) brone

(c)

bronchodilators using pre-measured or metered dose inhalation device;

sublingual nitroglycerin for unrelieved chest pain; must have intravenous access

established prior to administration;

(d) glucagon;

(e) situations may arise involving patients with uncommon conditions requiring specific out of hospital administered medications or procedures; family members or the designated caregiver trained and knowledgeable of the special needs of the patient should be recognized as the expert regarding the care of the patient; EMS can offer assistance in airway management appropriate to their level of licensure, IV access, and the administration of the patient's prescribed medications where appropriate only if the medication is in the EMS

provider's scope of practice; online (direct contact) medical control communication must be established with the medical control physician approving the intervention; EMS services are not expected to provide the prescribed medications for these special needs patients.

[7.27.11.8 NMAC - Rp, 7.27.11.8 NMAC, 12/12/2017; A, xx/xx/2021]

7.27.11.9 APPROVED TRAINING PROGRAMS: "Approved emergency medical services training program" means a New Mexico emergency medical services training program that is sponsored by a post-secondary educational institution, is accredited by [the-]a bureau approved national accrediting organization for emergency medical services or active in the accreditation process, and is approved by the joint organization on education (JOE) and participates in the joint organization on education. Currently, there are [five]six approved EMS training programs.

A. Emergency medical services academy. University of New Mexico, (700 Camino De Salud NE., Albuquerque, New Mexico 87106, Tel: 505-272-5757). The EMS academy is designated as the lead training agency for providers in New Mexico as stated in Section 24-10B-12 NMSA 1978. The EMS academy teaches formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

B. Dona Ana community college. New Mexico state university, (Box 30001, Las Cruces, NM 88003-000 1, Tel: 505-527-7530). Dona Ana community college teaches formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

C. Eastern New Mexico university. EMS program, (Box 6000, Roswell, NM 88202-6000, Tel: 505-624-7000). The eastern New Mexico university teaches formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

D. Central New Mexico community college. EMS program, (525 Buena Vista Rd. SE, Albuquerque, NM 87106, Tel: 505-224-4000). Central New Mexico community college teaches formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

E. San Juan college EMS program. (4601 College Blvd; Farmington, NM 87402; 505-566-3857). San Juan College conducts formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

F. Santa Fe community college. EMS Program, (6401 Richards Ave, Santa Fe, NM 87508, 505-428-1820) SFCC conducts formal EMS education courses including EMS first responder, EMT-basic, EMT-intermediate, and EMT-paramedic.

[7.27.11.9 NMAC - Rp, 7.27.11.9 NMAC, 12/12/2017; A, xx/xx/2021]

7.27.11.10 SPECIAL SKILLS APPLICATION AND REPORTING PROCEDURES:

A. Purpose: Special skills are those skills, procedures, and medications that are requested by an EMS service to enhance emergency treatment capabilities beyond the normal scope of practice, as defined in the Emergency Medical Services Act. Use the enclosed procedures for application, reporting and renewal for special skills. Applications are reviewed and approved or disapproved by the medical direction committee, and once approved, become a legally recognized addition to the service capabilities.

B. General: All levels of EMS personnel, including licensed EMS first responders and all levels of licensed EMTs are eligible for special skills consideration for any procedure, skill or medication.

C. Application procedure: The EMS service medical director, or his designee, shall coordinate with the EMS service director, and shall apply for special skills to the EMS medical direction committee.

D. Application document: The application document for a special skill must be tailored to the level of the request. While the degree of detail in each section may vary to match the nature of the skill requested, all applications should include the following elements, in order:

(1) application cover page: titled to state the requested special skill, date of application, name of service, service director name and medical director name;

(2) contact information page: must include address and contact information for the service, service director and medical director;

(3) letters of support: must include individual letters of support from the service director and medical director; additional letters of support from the local medical community or evidence of notification of the local medical community may be required; the need for letters of notification and support from the local medical community and who provides the letters must be adjusted to match the nature of the special skill requested;

(4) service description: provide a concise description of the EMS service; this includes such items as basic call demographics relevant to the applicant, level of licensure of providers and names and locations of the primary receiving medical facilities;

(5) description of the special skill: provide a description of the procedure, medication or requested skill; include information on risks, benefits, indications and contraindications;

(6) justification and statement of need: provide a statement explaining why the special skill is needed; this should include a description of the current medical intervention or alternative practice to the special skill and a risk or benefit analysis that supports the special skill requested; the estimated number of potential interventions per year, other relevant statistical data and a statement indicating the level of current scientific information/studies to support the requested special skill; the level of scientific justification can be adjusted to match the level of the special skill requested;

(7) protocol: provide a copy of the treatment protocol; include other operational protocols relevant to the special skill, if applicable;

(8) training: provide a training syllabus; this must include learning objectives and the training hours for initial and continuing education; this section should also include a description of the instructors, how training will be completed, and a description of the method used to initially evaluate the skill; once initial training is completed, a list of trained and approved personnel shall be provided to the medical direction committee; these special skill authorized licensed EMS personnel must appear on the service's personnel list on the *New Mexico EMS tracking and reporting system database*.

(9) QA/QI program: provide a description of the QA/QI process for the special skill, including frequency of evaluation, names and qualifications of the personnel involved in the process; include a copy of the evaluation tool or forms that will be used, if applicable; and

(10) the application and all supporting documentation shall be submitted to the EMS bureau, attn: [state-]EMS [training coordinator]program manager.

E. Applicants may involve the EMS regional offices when preparing a special skill request and include a letter evidencing regional review. Applicants shall forward a copy of their application to their EMS regional office when completed.

F. Upon receipt, the state EMS medical director and state EMS [training coordinator]program manager will review the application. The service will be notified if the application is found to be incomplete or to contain significant errors.

G. Applications must be received at the bureau at least [45]30 days prior to the next regularly scheduled medical direction committee meeting to be placed on the agenda of that meeting for consideration by the medical direction committee.

H. The medical direction committee shall take action on all special skills applications on the agenda at their regularly scheduled meeting. The medical direction committee may take the following actions on the application: approved with limitations or restrictions, denied or tabled with a request for a formal presentation or additional information by the requesting service medical director or their designee.

I. The medical direction committee may give an approval subject to specific conditions, limitations or restrictions. This may include a written and practical examination.

J. Within 10 working days following the decision of the medical direction committee, the state EMS [training coordinator]program manager shall provide a written or email response to the applicant regarding the action of the medical direction committee.

K. Special skills may not be utilized until receipt of the special skill approval letter from the bureau any specific conditions or limitations will be evidenced in the approval letter from the bureau.

L. Monitoring: It is expected that EMS services with approved special skills will continuously comply with the requirements of their application and approval letter. This includes, but is not limited to, such items as training curricula, approved instructors, quality assurance, protocols and data collection. Any changes to the approved application shall be sent to the state EMS [training coordinator]program manager for concurrence/coordination with the medical direction committee.

M. The medical direction committee may immediately suspend or revoke special skill privileges for an individual or service that loses medical direction, or fails to comply with the stated requirements, or for any other reason to protect the health and welfare of the people of New Mexico.

N. If a new medical director assumes control of a service with an active special skill program, the bureau shall receive a letter of support from the new medical director within 30 days or the special skill approval may be withdrawn.

O. The service shall maintain a current list of all providers trained and approved to utilize the special skill. This list must be provided to the bureau upon request.

P. Reporting: The service shall provide to the [state EMS training coordinator]EMS program manager periodic written special skill reports. During the first year, the [report shall be due semi annually, occurring on June 1 and December 1.] EMS bureau or medical direction committee may request a semi-annual report; [S]subsequent reports shall be due annually on June 1. The EMS bureau or medical direction committee may request a report at any time. The medical direction committee may excuse an agency from the yearly report based on adequate surveillance being available from the state patient care report database.

Q. Report document: The written special skill report shall include the following minimum elements:

(1) report cover page: titled to state the special skill reported, date, name of service, service director and medical director;

(2) contact information page: shall include address and contact information for the service, service director and medical director;

(3) letters of support: must include individual letters of continued support from the service director and service medical director;

(4) statistics and outcome data: provide data on the utilization and patient outcomes involving the special skill; do not include patient identifiers; all adverse outcomes related to the special skill must be reported;

(5) continuing education: provide evidence of the continuing education program and refresher program;

(6) personnel list: provide a list of all personnel authorized to perform the special skill; these special skill authorized licensed EMS personnel must appear on the service's personnel list required for the *New Mexico EMS tracking and reporting system database*.

(7) QA/QI program: provide evidence of the ongoing QA/QI program;

(8) renewal: during a regularly scheduled meeting, the medical direction committee shall review all ongoing individual special skills programs on their three year anniversary and make a determination on renewal;

(9) if the medical direction committee determines not to provide automatic renewal on an ongoing special skill program, the state EMS [training coordinator]program manager shall provide a written notification to the service director and the service medical director within 10 working days; and

(10) the special skills program will be placed on the agenda of the next, or subsequent, regularly scheduled meeting of the medical direction committee and final determination regarding renewal will be made.

R. Special skills programs will remain active until a final determination regarding renewal has been made.

Special skills application:

- (1) general section;
- (2) EMS service name;
- (3) address;
- (4) service chief/director;
- (5) contact phone number;
- (6) physician medical director;
- (7) physician/medical director contact phone number;
- (8) special skill proposed;
- (9) level of licensure necessary for special skill;
- (10) estimated number of personnel to be trained;
- (11) estimated date of initial training;
- (12) training/quality assurance;
- (13) describe or identify the curriculum, including learning objectives, training hours, etc.;
- (14) please identify the lead instructor and provide a brief summary of their qualifications or

attach a resume;

S.

- (15) resumes required for new instructors;
- (16) if training/experience is required, provide a letter of commitment from the supporting

institution;

- (17) describe or attach a proposed continuing education plan;
- (18) attach a description of quality assurance plan, including periodic case reviews and

ongoing problems;

- (19) identification and steps for remedial action if necessary;
- (20) signatures; person completing the application, service chief/service director and medical

director;

(21) submit [10-]digital copies of the application in its entirety to: EMS bureau, state EMS [training coordinator]program manager, (1301 Siler Rd., Building F, Santa Fe, NM 87507) or as directed by the EMS bureau;

(22) submit one copy to the regional office. [7.27.11.10 NMAC - Rp, 7.27.11.10 NMAC, 12/12/2017; A, xx/xx/2021]